Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florence Lerebours

Showing results (21-30 of 100) with videos related to

Pageof 10
Sort By:
Cancer|August 1, 2009
18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancerJean-Louis Alberini, Florence Lerebours, Myriam Wartski, et al.
International Journal of Radiation Oncology, Biology, Physics|March 8, 2011
Radiotherapy for stage II and stage III breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomyRomuald Le Scodan, Jessica Selz, Denise Stevens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2003
Two prognostic groups of inflammatory breast cancer have distinct genotypesFlorence Lerebours, Philippe Bertheau, Ivan Bieche, et al.
Oncology Reports|July 14, 2005
Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancerPhilippe Bertheau, Florence Lerebours, Nicolas Mounier, et al.
Frontiers in Oncology|December 17, 2020
PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast CancerAlexandre Bertucci, François Bertucci, Christophe Zemmour, et al.
International Journal of Breast Cancer|June 14, 2013
Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 StudyFrançois-Clément Bidard, Lisa Belin, Suzette Delaloge, et al.
Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society|July 10, 2016
Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas SubtypesDidier Meseure, Sophie Vacher, Kinan Drak Alsibai, et al.
Genes & Cancer|August 16, 2012
Identification of new candidate therapeutic target genes in triple-negative breast cancerMathilde Glénisson, Sophie Vacher, Céline Callens, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 21, 2011
Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot studyNina Mortazavi-Jehanno, Anne-Laure Giraudet, Laurence Champion, et al.
International Journal of Cancer|March 26, 2013
miRNA expression profiling of inflammatory breast cancer identifies a 5-miRNA signature predictive of breast tumor aggressivenessFlorence Lerebours, Geraldine Cizeron-Clairac, Aurelie Susini, et al.
Pageof 10

Showing results (21-30 of 100) with videos related to

Sort By:
Pageof 10
Cancer|August 1, 2009
18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancerJean-Louis Alberini, Florence Lerebours, Myriam Wartski, et al.
International Journal of Radiation Oncology, Biology, Physics|March 8, 2011
Radiotherapy for stage II and stage III breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomyRomuald Le Scodan, Jessica Selz, Denise Stevens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2003
Two prognostic groups of inflammatory breast cancer have distinct genotypesFlorence Lerebours, Philippe Bertheau, Ivan Bieche, et al.
Oncology Reports|July 14, 2005
Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancerPhilippe Bertheau, Florence Lerebours, Nicolas Mounier, et al.
Frontiers in Oncology|December 17, 2020
PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast CancerAlexandre Bertucci, François Bertucci, Christophe Zemmour, et al.
International Journal of Breast Cancer|June 14, 2013
Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 StudyFrançois-Clément Bidard, Lisa Belin, Suzette Delaloge, et al.
Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society|July 10, 2016
Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas SubtypesDidier Meseure, Sophie Vacher, Kinan Drak Alsibai, et al.
Genes & Cancer|August 16, 2012
Identification of new candidate therapeutic target genes in triple-negative breast cancerMathilde Glénisson, Sophie Vacher, Céline Callens, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 21, 2011
Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot studyNina Mortazavi-Jehanno, Anne-Laure Giraudet, Laurence Champion, et al.
International Journal of Cancer|March 26, 2013
miRNA expression profiling of inflammatory breast cancer identifies a 5-miRNA signature predictive of breast tumor aggressivenessFlorence Lerebours, Geraldine Cizeron-Clairac, Aurelie Susini, et al.
Pageof 10